| Title |
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, October 2017
|
| DOI | 10.1007/s10549-017-4538-4 |
| Pubmed ID | |
| Authors |
V. Bernstein, S. L. Ellard, S. F. Dent, D. Tu, M. Mates, S. K. Dhesy-Thind, L. Panasci, K. A. Gelmon, M. Salim, X. Song, M. Clemons, D. Ksienski, S. Verma, C. Simmons, H. Lui, K. Chi, H. Feilotter, L. J. Hagerman, L. Seymour |
| Abstract |
Pelareorep, a serotype 3 reovirus, has demonstrated preclinical and early clinical activity in breast cancer and synergistic cytotoxic activity with microtubule targeting agents. This multicentre, randomized, phase II trial was undertaken to evaluate the efficacy and safety of adding pelareorep to paclitaxel for patients with metastatic breast cancer (mBC). Following a safety run-in of 7 patients, 74 women with previously treated mBC were randomized either to paclitaxel 80 mg/m(2) intravenously on days 1, 8, and 15 every 4 weeks plus pelareorep 3 × 10(10) TCID50 intravenously on days 1, 2, 8, 9, 15, and 16 every 4 weeks (Arm A) or to paclitaxel alone (Arm B). Primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate, overall survival (OS), circulating tumour cell counts, safety, and exploratory correlative analyses. All comparisons used a two-sided test at an alpha level of 20%. Survival analyses were adjusted for prior paclitaxel. Final analysis was performed after a median follow-up of 29.5 months. Pelareorep was well tolerated. Patients in Arm A had more favourable baseline prognostic variables. Median adjusted PFS (Arm A vs B) was 3.78 mo vs 3.38 mo (HR 1.04, 80% CI 0.76-1.43, P = 0.87). There was no difference in response rate between arms (P = 0.87). Median OS (Arm A vs B) was 17.4 mo vs 10.4 mo (HR 0.65, 80% CI 0.46-0.91, P = 0.1). This first, phase II, randomized study of pelareorep and paclitaxel in previously treated mBC did not show a difference in PFS (the primary endpoint) or RR. However, there was a significantly longer OS for the combination. Further exploration of this regimen in mBC may be of interest. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 101 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 12% |
| Student > Bachelor | 11 | 11% |
| Student > Master | 8 | 8% |
| Student > Ph. D. Student | 7 | 7% |
| Student > Doctoral Student | 6 | 6% |
| Other | 21 | 21% |
| Unknown | 36 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 24% |
| Biochemistry, Genetics and Molecular Biology | 12 | 12% |
| Agricultural and Biological Sciences | 7 | 7% |
| Immunology and Microbiology | 6 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 7 | 7% |
| Unknown | 41 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 396. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2024.
All research outputs
#69,802
of 23,999,200 outputs
Outputs from Breast Cancer Research and Treatment
#17
of 4,815 outputs
Outputs of similar age
#1,632
of 329,184 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#2
of 63 outputs
Altmetric has tracked 23,999,200 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,815 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,184 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.